To our knowledge, this is the first report where Skp2 is compared with Jab1, p16, p21 and p62 in STS and the first evidence of its possible clinical relevance in STS patients regarding potential benefits for adjuvant treatment with chemotherapy or radiation in the subgroup of patients with high expression of Skp2. The gene discussed is SKP2; the disease is telomere syndrome.